DrugPatentWatch Database Preview
Dantrolene sodium - Generic Drug Details
What are the generic sources for dantrolene sodium and what is the scope of dantrolene sodium patent protection?
Dantrolene sodium has eight patent family members in five countries.
There are five drug master file entries for dantrolene sodium. Nine suppliers are listed for this compound.
Summary for dantrolene sodium
International Patents: | 8 |
US Patents: | 5 |
Tradenames: | 4 |
Applicants: | 7 |
NDAs: | 8 |
Drug Master File Entries: | 5 |
Suppliers / Packagers: | 9 |
Bulk Api Vendors: | 73 |
Clinical Trials: | 2,434 |
Patent Applications: | 3,324 |
Formulation / Manufacturing: | see details |
Drug Prices: | see low prices |
DailyMed Link: | dantrolene sodium at DailyMed |
Pharmacology for dantrolene sodium
Drug Class | Skeletal Muscle Relaxant |
Physiological Effect | Decreased Striated Muscle Contraction Decreased Striated Muscle Tone |
Medical Subject Heading (MeSH) Categories for dantrolene sodium
Synonyms for dantrolene sodium
1-(((5-(4-Nitrophenyl)-2-furanyl)methylene)amino)-2,4-imidazolidinedione |
1-(((E)-[5-(4-Nitrophenyl)-2-furyl]methylidene)amino)-2,4-imidazolidinedione # |
1-((5-(4-Nitrophenyl)furfurylidene)amino)imidazolidine-2,4-dione, sodium salt |
1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin |
1-((5-(p-nitrophenyl)furfurylidene)amino)hydantoin anion |
1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin sodium |
1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin sodium salt hydrate |
1-({(1E)-[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione |
1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione |
1-[(5--(p-Nitro-phenyl)-fur-furyl-idene)-amino]-hydan-toin sodium salt |
1-[(5-[p-Nitrophenyl]-furfurylidene)amino]hydantoin |
1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione |
1-[[[5-(4-Io>>u+/-(1/2))-2-ss>>a<<>>u]NC(1/4)x>>u degrees +/->>u]-2,4-ssassosso paragraph signthornI feminine AAENI |
1-[[[5-(4-Nitrophenyl)-2-furanyl]methylene]amino]-2,4-imidazolidinedione Sodium Salt Hemiheptahydrate |
1-[[[5-(4-Nitrophenyl)-2-furanyl]methylene]amino]-2,4-imidazolinedione sodium salt |
1-[[5-(p-Nitrophenyl)furfurylidene]amino]hydantoin |
1-[5-(4-nitro-phenyl)-furan-2-ylmethyleneamino]-imidazolidine-2,4-dione |
1-[5-(4-Nitrophenyl)furfurylideneamino]hydantoin Sodium Salt |
1-{(5-{p-nitrophenyl}furfurylidene)-amino}hydantoin sodium |
14663-23-1 |
2,4-Imidazolidinedione, 1-(((5-(4-nitrophenyl)-2-furanyl)methylene)amino)- |
2,4-Imidazolidinedione, 1-(((5-(4-nitrophenyl)-2-furanyl)methylene)amino)-, sodium salt |
2,4-Imidazolidinedione, 1-(((5-(4-nitrophenyl)-2-furanyl)methylene)amino)-, sodium salt, hydrate (2:7) |
2,4-Imidazolidinedione, 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]- |
2,4-Imidazolidinedione, 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-, sodium salt, hydrate |
24868-20-0 |
287M0347EV |
28F0G1E0VF |
2C14H9N4O5.2Na |
2C14H9N4O5.2Na.7H2O |
3-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)-2,5-dioxoimidazolidin-1-ide |
3-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]-5-oxo-4H-imidazol-2-olate |
63D231 |
663D231 |
7261-97-4 |
A817527 |
AB00053743_02 |
AB0011237 |
AB00513823 |
AC-25752 |
AC1O7G8U |
AC1O7GSO |
AC1OC9NE |
AKOS015895197 |
AKOS015895198 |
AKOS015902289 |
AKOS015963269 |
Ambap14663-23-1 |
anhydrous dantrolene sodium |
B6329 |
BC215665 |
BCBcMAP01_000067 |
BDBM200293 |
BIDD:GT0187 |
BPBio1_000246 |
BRD-K81272440-001-02-6 |
BRD-K81272440-236-05-1 |
BRN 0705189 |
BSPBio_000222 |
BSPBio_001305 |
BSPBio_003074 |
C-22163 |
C06939 |
C07933 |
C14H10N4O5 |
C14H9N4O5.Na |
CCG-204516 |
CCG-220291 |
CCG-221728 |
CCG-40324 |
CHEBI:184644 |
CHEBI:4317 |
CHEBI:4318 |
CHEBI:59697 |
CHEMBL1201288 |
CHEMBL928 |
cid_6604728 |
CPD000326766 |
CS-5234 |
D 9175 |
D02274 |
D02347 |
D0I8DD |
D3996 |
Dantamacrin |
Dantrium |
Dantrium (TN) |
Dantrium Intravenous |
Dantrix |
Dantrolen (TN) |
dantrolene |
Dantrolene (sodium salt) |
Dantrolene (sodium) |
Dantrolene (USAN/INN) |
Dantrolene [USAN:BAN:INN] |
Dantrolene [USAN:INN:BAN] |
dantrolene anion |
Dantrolene Sodium (anhydrous) |
Dantrolene sodium (USAN) |
Dantrolene sodium [USAN:BAN:JAN] |
Dantrolene sodium [USAN:USP:BAN:JAN] |
Dantrolene sodium anhydrous |
Dantrolene sodium hemiheptahydrate |
Dantrolene Sodium Hydrate |
Dantrolene sodium hydrate (JP17) |
Dantrolene sodium salt |
Dantrolene, Sodium Salt |
dantrolene(1-) |
Dantrolenesodium |
Dantroleno |
Dantroleno [INN-Spanish] |
Dantrolenum |
Dantrolenum [INN-Latin] |
DB01219 |
disodium 3-[(E)-[5-(4-nitrophenyl)-2-furanyl]methylideneamino]-5-oxo-4H-imidazol-2-olate heptahydrate |
disodium 3-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]-5-oxidanylidene-4H-imidazol-2-olate heptahydrate |
disodium;1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidin-3-ide-2,4-dione;heptahydrate |
EINECS 230-684-8 |
EINECS 238-706-8 |
EU-0100424 |
F 440 |
F-368 |
F-440 |
F64QU97QCR |
FT-0082847 |
HMS1361B07 |
HMS1568L04 |
HMS1791B07 |
HMS1989B07 |
HMS2092N12 |
HMS2095L04 |
HMS3261E10 |
HMS3266G14 |
HMS3402B07 |
HMS502M20 |
HSDB 3050 |
HY-14657 |
Hydantoin, 1-((5-(p-nitrophenyl)furfurylidene)amino)- |
Hydantoin, 1-((5-(p-nitrophenyl)furfurylidene)amino)-, sodium salt |
Hydantoin, 1-((5-(p-nitrophenyl)furfurylidene)amino)-, sodium salt, hydrate (2:7) |
I06-0335 |
I06-0336 |
I14-13402 |
IDI1_000898 |
IDI1_033775 |
J-015708 |
Lopac0_000424 |
LS-174074 |
LS-76264 |
LS-76265 |
MFCD00079130 |
MLS000859905 |
MLS002153441 |
MolPort-003-666-797 |
MolPort-006-069-178 |
NCGC00024622-02 |
NCGC00024622-03 |
NCGC00024622-04 |
NCGC00093847-01 |
NCGC00163132-01 |
NCGC00163402-01 |
NCGC00163402-02 |
NCGC00163402-03 |
NCGC00188950-01 |
NCGC00261109-01 |
NSC-758403 |
NSC758403 |
OZOMQRBLCMDCEG-VIZOYTHASA-N |
Pharmakon1600-01503209 |
potassium 1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)-4-oxo-5H-imidazol-2-olate |
Prestwick2_000291 |
Prestwick3_000291 |
R452 |
Ryanodex |
SAM002703135 |
SBI-0050409.P003 |
SCHEMBL12417164 |
SCHEMBL2903719 |
SCHEMBL40893 |
SMR000326766 |
sodium 1-[(E)-{[5-(4-nitrophenyl)furan-2-yl]methylidene}amino]-4-oxo-5H-imidazol-2-olate |
sodium 3-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)-2,5-dioxoimidazolidin-1-ide |
sodium 3-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)-2,5-dioxoimidazolidin-1-ide--water (2/7) |
sodium 3-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]-5-oxo-4H-imidazol-2-olate |
Sodium dantrolene |
Sodium, Dantrolene |
Spectrum5_001752 |
SR-01000076241 |
SR-01000076241-1 |
ST51052737 |
Tox21_500424 |
TR-005822 |
UNII-287M0347EV |
UNII-28F0G1E0VF |
UNII-F64QU97QCR |
ZINC7997966 |
US Patents and Regulatory Information for dantrolene sodium
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Impax Labs | DANTROLENE SODIUM | dantrolene sodium | CAPSULE;ORAL | 076856-002 | Mar 1, 2005 | AB | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
Par Sterile Products | DANTRIUM | dantrolene sodium | CAPSULE;ORAL | 017443-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
Eagle Pharms | RYANODEX | dantrolene sodium | FOR SUSPENSION;INTRAVENOUS | 205579-001 | Jul 22, 2014 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
Impax Labs | DANTROLENE SODIUM | dantrolene sodium | CAPSULE;ORAL | 076856-001 | Mar 1, 2005 | AB | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for dantrolene sodium
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Par Sterile Products | DANTRIUM | dantrolene sodium | CAPSULE;ORAL | 017443-002 | Approved Prior to Jan 1, 1982 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Par Sterile Products | DANTRIUM | dantrolene sodium | INJECTABLE;INJECTION | 018264-001 | Approved Prior to Jan 1, 1982 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Par Sterile Products | DANTRIUM | dantrolene sodium | CAPSULE;ORAL | 017443-001 | Approved Prior to Jan 1, 1982 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Par Sterile Products | DANTRIUM | dantrolene sodium | CAPSULE;ORAL | 017443-003 | Approved Prior to Jan 1, 1982 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Non-Orange Book US Patents for dantrolene sodium
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
9,789,090 | Treatment using dantrolene | ➤ Try a Free Trial |
9,271,964 | Treatment using dantrolene | ➤ Try a Free Trial |
9,603,840 | Treatment using dantrolene | ➤ Try a Free Trial |
Patent No. | Title | Estimated Patent Expiration |
International Patents for dantrolene sodium
Country | Document Number | Estimated Expiration |
---|---|---|
Australia | 2004262507 | ➤ Try a Free Trial |
European Patent Office | 1603513 | ➤ Try a Free Trial |
Japan | 2007525439 | ➤ Try a Free Trial |
Japan | 4880449 | ➤ Try a Free Trial |
Country | Document Number | Estimated Expiration |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:









Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.